Alnylam

Press Releases

Jul 09,2019
Summary ToggleFirst-in-class ‘gene-silencing’ therapy approved for NHS use in England to treat hereditary form of amyloidosis
PDF Version
Jul 01,2019
Summary ToggleAlnylam Submits Marketing Authorization Application to the European Medicines Agency for Givosiran for the Treatment of Acute Hepatic Porphyria
PDF Version
Jun 24,2019
Summary ToggleAlnylam Presents New ONPATTRO® (patisiran) Results at the 2019 Peripheral Nerve Society Annual Meeting
PDF Version
Jun 21,2019
Summary ToggleAlnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery
PDF Version
Jun 18,2019
Summary ToggleAlnylam Announces Approval in Japan of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
PDF Version
Jun 17,2019
Summary ToggleAlnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
PDF Version
Jun 13,2019
Summary ToggleAlnylam to Report New Clinical Results for ONPATTRO® (patisiran) at Peripheral Nerve Society (PNS) Annual Meeting and the 5th Congress of the European Academy of Neurology (EAN)
PDF Version
Jun 05,2019
Summary ToggleAlnylam Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Givosiran for the Treatment of Acute Hepatic Porphyria
PDF Version
May 31,2019
Summary ToggleAlnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
PDF Version
May 30,2019
Summary ToggleAlnylam to Webcast Presentations at Upcoming June Investor Conferences
PDF Version
May 29,2019
Summary ToggleAlnylam Announces New Leadership Appointments
PDF Version
May 09,2019
Summary ToggleAlnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019
PDF Version
May 01,2019
Summary ToggleAlnylam Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity
PDF Version
Apr 30,2019
Summary ToggleAlnylam Highlights Progress on Global Market Access for ONPATTRO (patisiran)
PDF Version
Apr 23,2019
Summary ToggleAlnylam to Webcast Conference Call Discussing First Quarter 2019 Financial Results
PDF Version
Apr 15,2019
Summary ToggleAlnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
PDF Version
Apr 12,2019
Summary ToggleAlnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
PDF Version
Apr 08,2019
Summary ToggleAlnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
PDF Version
Apr 08,2019
Summary ToggleAlnylam and Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration
PDF Version
Mar 27,2019
Summary ToggleAlnylam to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress™
PDF Version
Displaying 21 - 40 of 1045 results
View all releases

Search

: (Common):

Price:
Change (%):
Volume:
Data as of
Copyright NASDAQ. Minimum 15 minutes delay
Learn More